Roche Wins FDA Approval for Wilserdly in ESR1-Mutated Breast Cancer

Share on Social Media

Roche's Wilserdly (giredestrant) receives FDA approval with everolimus for ESR1-mutated advanced breast cancer.
Image: Pixels

FDA approves Roche’s Wilserdly (giredestrant) with everolimus for ESR1-mutated advanced breast cancer after phase III evERA showed a 62% reduction in progression or death risk.

Written By: Siddhi Bhadekar, M. Pharm (QA)

Reviewed By: Pharmacally Editorial Team

Roche announced on November 16, 2026, that the U.S. Food and Drug Administration (FDA) approved Wilserdly (giredestrant), an oral selective estrogen receptor degrader (SERD), in combination with everolimus for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval, granted four weeks ahead of the FDA’s goal date, marks the first regulatory authorization for giredestrant.

The decision was supported by the phase III evERA Breast Cancer trial (NCT05306340), in which giredestrant plus everolimus significantly improved progression-free survival (PFS) compared with standard endocrine therapy plus everolimus.

FDA-Approved Indication and Regulatory Review

The approval covers patients with ESR1 mutations detected by an FDA-authorized test whose disease has recurred during or after endocrine-based adjuvant therapy or progressed following at least one endocrine-based regimen in the metastatic setting.

The FDA also authorized FoundationOne Liquid CDx as a companion diagnostic to identify specific ESR1 mutations in circulating tumor DNA (ctDNA).

The application underwent review through Project Orbis, involving Health Canada and Israel’s Ministry of Health, and used the FDA’s voluntary Assessment Aid.

The recommended giredestrant dose is 30 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. Everolimus dosing follows its prescribing information.

Phase III evERA Trial: Clinical Evidence Supporting Approval

The randomized, open-label, multicenter evERA trial enrolled 373 patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer following prior CDK4/6 inhibitor and endocrine therapy.

Patients received giredestrant 30 mg daily (n=183) or physician’s choice of endocrine therapy comprising exemestane, fulvestrant or tamoxifen (n=190). Both groups received everolimus 10 mg daily.

Among 207 patients with ESR1-mutated tumors, 102 received giredestrant plus everolimus and 105 received comparator therapy plus everolimus. Pre- and perimenopausal women and men without prior bilateral orchiectomy also received a GnRH agonist.

The trial evaluated investigator-assessed PFS using RECIST version 1.1, with overall survival (OS) and objective response rate (ORR) among additional efficacy endpoints.

Giredestrant Reduced the Hazard of Progression or Death by 62%

In the ESR1-mutated population, median PFS reached 10 months with giredestrant plus everolimus versus 5.5 months with comparator therapy, representing a 62% reduction in the hazard of progression or death (HR 0.38; 95% CI 0.27–0.54; p<0.0001).

Objective response rates were 27% and 14%, respectively.

In the overall intention-to-treat population, median PFS was 8.8 versus 5.5 months (HR 0.56; 95% CI 0.44–0.71), indicating a treatment benefit beyond the ESR1-mutated subgroup, although the effect was more pronounced among patients carrying ESR1 mutations.

OS data remained immature at the primary PFS analysis. The results were published in The New England Journal of Medicine.

Safety Findings and Prescribing Warnings

The FDA identified stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis and nausea as common adverse reactions occurring in at least 20% of patients receiving giredestrant plus everolimus.

Common laboratory abnormalities included decreased blood cell counts and electrolyte levels, increased liver enzymes and elevated creatinine.

The prescribing information includes warnings and precautions for bradycardia and embryo-fetal toxicity. Everolimus-associated adverse effects, particularly stomatitis and pneumonitis, remain relevant to treatment monitoring.

Giredestrant Mechanism and Combination Rationale

Giredestrant is a next-generation oral SERD and full ER antagonist designed to inhibit estrogen signalling by blocking estrogen binding and promoting receptor degradation.

ESR1 mutations can sustain estrogen receptor activity despite endocrine treatment, contributing to acquired resistance in advanced breast cancer.

Roche identifies activation of the PI3K/AKT/mTOR pathway alongside continued ER dependence as an important resistance mechanism following endocrine therapy and CDK4/6 inhibition.

Combining giredestrant with the mTOR inhibitor everolimus is intended to address these complementary signalling pathways. Preclinical findings support enhanced antiproliferative activity, although the clinical benefit must be interpreted within the evERA trial population.

Pending Adjuvant Regulatory Decision

Roche is also pursuing an expanded role for giredestrant in early-stage breast cancer.

The FDA accepted the company’s New Drug Application for adjuvant giredestrant under Priority Review based on the phase III lidERA study (NCT04961996), with a PDUFA goal date of November 30, 2026.

The application concerns adults with ER-positive, HER2-negative stage I–III breast cancer at intermediate to high risk of recurrence.

If approved, giredestrant could become the first SERD authorized in both adjuvant and advanced breast cancer settings. This potential expansion remains subject to a separate FDA decision.

Clinical Interpretation

The evERA findings establish a clinically meaningful PFS improvement in ESR1-mutated advanced breast cancer following prior endocrine therapy and CDK4/6 inhibition.

The 4.5-month difference in median PFS supports the benefit of replacing conventional endocrine therapy with giredestrant while maintaining everolimus treatment.

However, the open-label design, investigator-assessed PFS and immature OS data limit conclusions regarding long-term survival benefit. The study also does not establish superiority over other oral SERDs or alternative treatment sequences.

Importantly, median PFS of 10 months indicates that disease progression remains a substantial challenge despite improved disease control.

The approval introduces another biomarker-directed treatment option, with ctDNA-based ESR1 testing central to patient selection. Longer follow-up, including OS and quality-of-life outcomes, will help define the combination’s place in clinical practice.

References

FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer, Roche, November 16, 2026.

U.S. Food and Drug Administration. FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. November 16, 2026.

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus Everolimus in Participants with Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer), ClinicalTrials.gov ID NCT05306340

Mayer E, et al. Giredestrant plus Everolimus in Advanced Breast Cancer. N Engl J Med. 2026;395:1285–1298. DOI: 10.1056/NEJMoa2602457.

About the Writer

Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.


Share on Social Media
Scroll to Top